Hexagon Bio
A biotechnology company using computational genomics to discover novel small-molecule medicines from microbial genomes.
Website: https://www.hexagonbio.com/
Cover Block
Public sources
| Name | Hexagon Bio |
| Tagline | A biotechnology company using computational genomics to discover novel small-molecule medicines from microbial genomes. |
| Headquarters | Menlo Park, United States |
| Founded | 2016 |
| Stage | Series B |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | $100M+ (total disclosed ~$185,300,000) |
Links
Public sources
- Website: https://www.hexagonbio.com/
- LinkedIn: https://www.linkedin.com/company/hexagon-bio/
- X / Twitter: https://twitter.com/hexagonbio
Executive Summary
Public sources
Hexagon Bio is a biotechnology company using computational genomics to mine microbial genomes for novel small-molecule medicines, a strategy that has attracted over $185 million in venture capital for its potential to unlock a new generation of antibody-drug conjugate payloads [Hexagon Bio, September 2020] [Hexagon Bio, February 2023]. Founded in 2016, the company's wedge lies in its systematic, data-driven approach to natural product discovery, moving beyond traditional screening to analyze the genetic blueprints of fungi and other microbes at scale [Fierce Biotech, September 2021]. Its platform identifies secondary metabolites and protein targets, with a current focus on developing next-generation oncology therapies, specifically novel cytotoxic payloads for antibody-drug conjugates designed to overcome existing resistance mechanisms [Hexagon Bio, February 2023].
The founding team brings a specific blend of genomics, data science, and chemistry. CEO Maureen Hillenmeyer previously directed the Genomes to Natural Products program at Stanford, co-founder Brian Naughton was a founding scientist at 23andMe, and co-founder Yi Tang is a professor of chemical engineering at UCLA, anchoring the company's academic and commercial DNA [Forbes, June 2024] [Hexagon Bio]. The business model appears to combine internal drug development with potential partnership or licensing deals, though no specific pharmaceutical customers or transactions are publicly disclosed. Over the next 12-18 months, the key signals to monitor are the progression of its internal ADC programs, the expansion of its clinical advisory board, and any disclosed partnerships that validate its platform's output [Yahoo Finance].
Independently corroborated -- Core facts confirmed by company announcements and third-party reporting.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series B |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $100M+ (total disclosed ~$185,300,000) |
How the Company Got Here
Public sources
Hexagon Bio was founded in 2016 in Menlo Park, California, on a premise that merges computational biology with natural product discovery. The company's founding narrative, as presented in its Series A announcement, positions it as a venture built to systematically mine microbial genomes for novel small-molecule medicines, moving beyond the limitations of traditional screening methods [Hexagon Bio, September 2020]. This origin is anchored by a founding team with specific domain expertise in genomics, data science, and synthetic biology.
The company's key public milestones are tied to its funding rounds, which have consistently been framed as capital to expand its proprietary platform and advance its internal pipeline. The $47 million Series A in September 2020 was led by The Column Group and was intended to fund the build-out of a "first-of-its-kind proprietary genomics database" and the initial drug discovery team [Hexagon Bio, September 2020]. This was followed by a $61 million round in September 2021, led by Nextech Invest, which brought in new investors SoftBank and Casdin Capital [Fierce Biotech, September 2021]. The most recent disclosed round is a $77.3 million Series B, announced in February 2023, aimed at expanding the computational platform and advancing drug candidates [Hexagon Bio, February 2023].
A notable operational milestone, signaling a strategic evolution, was the formation of a clinical advisory board, reported in 2024 [Yahoo Finance]. This move, coupled with recent hiring for contract roles in bioconjugation and bioanalysis, suggests the company is progressing from a pure discovery platform toward translational drug development activities [Greenhouse, May 2026] [Greenhouse, February 2026].
Independently corroborated -- Confirmed by company announcements and independent media.
Product and Technology
Sources and analysis
The core of Hexagon Bio is a computational genomics platform designed to systematically mine the genomes of fungi and other microbes for novel small-molecule medicines. The company describes its approach as turning "nature's genomes into medicines," moving beyond traditional natural product screening by starting with genetic sequence data to predict and identify secondary metabolites with therapeutic potential [Hexagon Bio]. This platform connects microbial DNA to drug-like small molecules, with a stated initial focus on discovering novel payloads for antibody-drug conjugates in oncology [Hexagon Bio, September 2020].
Current public materials emphasize the development of next-generation oncology ADCs, aiming to overcome resistance to existing payloads and expand the range of treatable cancers [Hexagon Bio, February 2023]. The platform's output is a pipeline of microbial-genome-derived small molecules, which the company is advancing internally as drug candidates. A shift toward clinical development is suggested by the formation of a clinical advisory board and recent hiring for roles in bioconjugation, bioanalysis, and ADC pharmacology [Yahoo Finance].
Inferred from active job postings, the technology stack appears to integrate several specialized components:
- A proprietary genomics database. Referred to as a "first-of-its-kind" database built from microbial genomes [Hexagon Bio, September 2020].
- A computational discovery engine. Job listings for Computational Biologists and Data Scientists mention work on evolutionary biology and natural-product genomics, while a Senior Software Engineer role is responsible for an internal platform called "Tracker" that powers the discovery engine [Greenhouse].
- Integrated wet-lab capabilities. Roles in fungal genetics, molecular biology, medicinal chemistry, and in vivo pharmacology indicate a closed-loop system where computational predictions are validated and optimized through biological and chemical experimentation [Greenhouse].
Independently corroborated -- Platform description and focus confirmed by multiple company announcements. Hiring inferences are based on publicly posted job requisitions.
Where the Demand Sits
Public sources The market for novel oncology therapeutics, particularly antibody-drug conjugates (ADCs), is expanding rapidly, driven by a persistent need to overcome drug resistance and improve targeted delivery. Hexagon Bio's focus on discovering new payloads from microbial genomes places it at the intersection of two high-growth segments: the ADC therapeutic market and the computational drug discovery platform space.
Third-party market sizing for the specific niche of natural-product-derived ADC payloads is not publicly available. However, broader market reports provide a relevant analog. The global ADC therapeutics market was valued at approximately $10.9 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of over 14% through 2030, according to a report from Grand View Research [Grand View Research, 2024]. This growth is underpinned by a robust clinical pipeline and recent high-value acquisitions, such as Pfizer's $43 billion acquisition of Seagen in 2023 [Pfizer, March 2023]. The computational biology and genomics market, which includes the discovery tools Hexagon employs, is also expanding, with one analysis estimating a market size of $15.2 billion in 2024 and a forecasted CAGR of 12.5% through 2030 [Precedence Research, 2024].
Several demand drivers are clear from industry coverage. First, the limitation of current ADC payloads, primarily tubulin inhibitors, is a well-documented bottleneck; tumors can develop resistance, and the toxicity profiles limit therapeutic windows [Nature Reviews Drug Discovery, 2022]. This creates a direct need for novel payloads with alternative mechanisms of action. Second, the renewed interest in natural products as a source of chemical diversity is a significant tailwind. After a period of decline, large pharmaceutical companies are returning to natural product screening, aided by modern genomics and bioinformatics to de-risk the discovery process [Journal of Natural Products, 2021]. Third, the continued investment in oncology R&D, which reached a record $200 billion globally in 2023, ensures a ready pool of capital for promising new modalities [IQVIA, 2024].
Adjacent and substitute markets influence the opportunity. Traditional small-molecule drug discovery remains the largest direct substitute, though it faces its own challenges with high failure rates in oncology. Cell and gene therapies represent another adjacent, high-growth area that competes for similar investor and pharma partner attention but addresses different patient populations and mechanisms. The market for drug discovery partnerships and platform licensing, where Hexagon would likely transact, is less formally sized but can be inferred from deal activity. For instance, the total value of biopharma discovery and platform partnerships exceeded $50 billion in upfront and milestone payments in 2023, according to industry analysts [Biopharma Dive, 2024].
Regulatory and macro forces are generally favorable but carry nuance. The FDA's Oncology Center of Excellence has established expedited pathways for innovative cancer therapies, which can benefit novel ADCs [FDA, 2023]. However, the regulatory bar for demonstrating a superior safety and efficacy profile for a new payload remains high. Macro forces include sustained venture capital interest in biotechnology, though the sector has seen a tightening of funding for preclinical-stage companies since 2022, placing a premium on capital efficiency and clear milestones [Silicon Valley Bank, 2024]. Geopolitical tensions, particularly concerning biotech supply chains and international collaboration, present a potential headwind for global operations.
ADC Therapeutics Market (2023) | 10.9 | $B
Computational Biology Market (2024) | 15.2 | $B
Biopharma Discovery Partnerships (2023) | 50 | $B
The chart illustrates the substantial addressable markets surrounding Hexagon's core activities. The figures for ADC therapeutics and computational biology are cited third-party estimates, while the partnership value is an annual aggregate of deal flow, indicating the scale of potential transactions. The key takeaway is that Hexagon operates within large and growing markets, but its specific wedge,mining fungal genomes for ADC payloads,occupies a narrower, unquantified segment where success will depend on technical execution rather than market size alone.
Lightly corroborated -- Market sizing relies on analogous third-party reports for broader categories; specific TAM for the company's niche is not publicly confirmed.
Competitive Landscape
Sources and analysis Hexagon Bio positions itself within a nascent but crowded segment of biotech, where its computational approach to mining microbial genomes for novel drug candidates is its primary differentiator against both traditional discovery houses and newer AI-native platforms.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Hexagon Bio | Computational genomics platform mining microbial (fungal) genomes for novel small-molecule ADC payloads and drug candidates. | Series B, $185.3M+ total disclosed. | Proprietary database linking microbial genomes to drug-like molecules; integrated fungal genetics and chemistry. | [Hexagon Bio, September 2020]; [Hexagon Bio, February 2023] |
| LifeMine Therapeutics | AI-powered platform mining fungal genomes for genetically encoded small-molecule medicines. | Series C, $175M+ total disclosed. | Focus on a proprietary fungal strain library and a fully integrated, AI-driven discovery-to-lead optimization engine. | [BioPharma Dive] |
| Adapsyn Bioscience | Machine learning and metabolomics platform for discovering novel natural products from microbial sources. | Seed, $5.5M disclosed. | Emphasis on metabolomic data and machine learning to identify and characterize novel compounds from environmental samples. | [Crunchbase] |
The competitive map for microbial genome mining is defined by two primary axes: the source of biological data and the computational methodology applied. In one segment, large pharmaceutical companies like Merck and Pfizer maintain internal natural product discovery groups, which rely on traditional culture-based screening of environmental samples. These incumbents possess immense distribution and capital but are often constrained by the limited chemical diversity of their historical libraries and slower, more empirical screening processes. In the adjacent challenger segment are AI-first drug discovery platforms such as Recursion Pharmaceuticals and Exscientia, which apply machine learning to high-throughput cellular imaging or chemical design. While these companies have advanced further into clinical trials, their focus is typically not on de novo discovery of novel natural product scaffolds from unexplored genomic data.
Hexagon's defensible edge today rests on its integrated platform, which combines a proprietary genomic database, specialized fungal genetics expertise, and a chemistry team focused on ADC payloads. The company's leadership in fungal genomics, anchored by CEO Maureen Hillenmeyer's background at Stanford, provides a talent moat in a niche area. This edge is durable if Hexagon continues to scale its database and demonstrate that its discovered molecules translate into viable drug candidates. However, it is perishable; the core genomic data, while proprietary, could be replicated over time by competitors with sufficient capital and biological sampling capabilities. The recent formation of a clinical advisory board and hiring for ADC-specific roles [Yahoo Finance] suggests Hexagon is attempting to convert its platform edge into a development edge, moving beyond pure discovery.
Hexagon's most significant exposure is to competitors with deeper pipelines or more advanced platform validation. LifeMine Therapeutics, a direct competitor, has also raised substantial capital and is advancing its own pipeline, creating a race to clinical proof-of-concept. LifeMine's public emphasis on a fully integrated, AI-driven platform could appeal to partners seeking a more automated discovery engine. Furthermore, Hexagon is exposed to the broader risk that the entire microbial mining category fails to produce clinically successful drugs, a scenario that would benefit adjacent AI discovery platforms with more diversified approaches or large pharma partners with internal fallback options.
The most plausible 18-month scenario involves increased partnership activity as platforms seek validation. The winner in this period will likely be the company that announces a major pharmaceutical collaboration or advances a lead candidate into preclinical development, thereby de-risking its platform for investors. If Hexagon can use its ADC payload focus to secure a partnership with an oncology-focused biopharma, it could solidify its position. Conversely, a loser in this scenario would be any platform that fails to transition from platform-building to tangible pipeline progress, risking a "platform purgatory" where its technology is viewed as interesting but unproven in generating clinical assets.
Lightly corroborated -- Competitor profiles and funding are confirmed via public sources, but direct comparative analysis of technical differentiators relies on company-reported positioning.
Opportunity
Public sources The prize for Hexagon Bio is the potential to become a primary source of novel payloads for the next generation of antibody-drug conjugates (ADCs), a multi-billion dollar drug class where innovation in cytotoxic agents is a critical bottleneck.
The headline opportunity is to establish a category-defining discovery platform that systematically converts the vast, untapped chemical diversity of microbial genomes into validated drug candidates. This outcome is reachable because the company has already demonstrated the ability to raise significant capital to build its platform, has assembled a team with deep expertise in the relevant computational and biological disciplines, and is actively hiring for late-stage drug development roles, signaling a transition from pure discovery to clinical asset generation [Hexagon Bio, February 2023] [Greenhouse, May 2026]. The focus on oncology ADCs provides a clear, high-value commercial endpoint for its discoveries.
Two distinct growth scenarios outline paths to scaling this platform.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform-as-a-Service Leader | Hexagon becomes the preferred discovery partner for large pharma, generating revenue through research collaborations and milestone payments while building a pipeline of wholly-owned assets. | A major licensing deal or multi-program alliance with a top-20 pharmaceutical company is announced. | The formation of a clinical advisory board and a joint venture with Corteva indicate an evolving partnership strategy and the ability to structure complex, long-term commercial agreements [Yahoo Finance] [Hexagon Bio]. |
| Integrated Biotech with a Blockbuster ADC | The company advances an internally discovered payload into a proprietary ADC that achieves clinical validation, leading to a lucrative acquisition or an independent path to market. | Positive preclinical data for a lead ADC candidate is published or presented at a major oncology conference. | Hiring for specific roles in bioconjugation, in vivo pharmacology, and medicinal chemistry shows a dedicated internal push toward developing clinical-stage assets [Greenhouse, August 2025] [Greenhouse]. |
What compounding looks like is a data-driven discovery flywheel. Each newly sequenced microbial genome and each experimentally validated molecule enriches the proprietary database, improving the predictive algorithms for finding the next candidate. This creates a data moat where the platform's value increases with scale, making it progressively harder for new entrants to replicate the breadth and depth of Hexagon's genomic-to-chemical mapping. Early evidence of this compounding is seen in the platform's expansion, funded by successive rounds of capital specifically earmarked for scaling the computational discovery engine [Hexagon Bio, September 2020] [Hexagon Bio, February 2023].
The size of the win can be framed by a credible comparable. LifeMine Therapeutics, a direct competitor also mining fungal genomes for drug discovery, completed a Series C round in 2022 at a valuation reported to be approximately $550 million [BioPharma Dive]. If Hexagon executes on its integrated biotech scenario and advances a promising ADC candidate toward the clinic, achieving a similar or greater valuation is a plausible outcome. In a platform-as-a-service scenario, the financial model could resemble that of discovery-stage biotechs like Nimbus Therapeutics, which has secured partnerships with companies like Takeda and Gilead worth hundreds of millions in potential milestones. A successful outcome in either path positions the company for a valuation well into the hundreds of millions, if not exceeding $1 billion, based on the precedent set by platform biotechs with advanced pipelines (scenario, not a forecast).
Lightly corroborated -- Opportunity framing is extrapolated from public strategy, hiring, and partnership signals; specific valuation comparables are drawn from a single source.
Sources
Public sources
[Hexagon Bio, September 2020] Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies | https://www.hexagonbio.com/series-a/
[Hexagon Bio, February 2023] Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules | https://www.hexagonbio.com/hexagon-bio-raises-77-3-million-series-b-financing-and-strengthens-leadership-to-expand-novel-computational-discovery-platform-and-advance-microbial-genome-derived-small-molecules/
[Fierce Biotech, September 2021] Fungi funding: Hexagon Bio snags $61M to test drugs from fungi for cancer, infectious diseases | https://www.fiercebiotech.com/biotech/fungi-funding-hexagon-bio-snags-61m-to-test-drugs-from-fungi-for-cancer-infectious-diseases
[Forbes, June 2024] 23andHim: The Untold Story Of 23andMe’s Third Co-Founder | https://www.forbes.com/sites/heatherwishartsmith/2024/06/25/23andhim-the-untold-story-of-23andmes-third-co-founder/
[Hexagon Bio] Hexagon Bio | https://www.hexagonbio.com/
[Yahoo Finance] Hexagon Bio announces formation of clinical advisory board | https://finance.yahoo.com/healthcare/articles/hexagon-bio-announces-formation-clinical-120000473.html
[Greenhouse, May 2026] Associate Scientist/Scientist I, Bioconjugation , 1-Year Contract Position | https://job-boards.greenhouse.io/hexagonbio/jobs/7754191003
[Greenhouse, February 2026] Bioanalytical Scientist I/Scientist II , 9-Month Contract Position | https://job-boards.greenhouse.io/hexagonbio/jobs/7629183003
[Greenhouse] Careers - Hexagon Bio | https://www.hexagonbio.com/careers/
[Grand View Research, 2024] Antibody Drug Conjugates Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market
[Pfizer, March 2023] Pfizer to Acquire Seagen | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-seagen
[Precedence Research, 2024] Computational Biology Market Size, Growth, Report 2024-2032 | https://www.precedenceresearch.com/computational-biology-market
[Nature Reviews Drug Discovery, 2022] Antibody-drug conjugates for cancer therapy | https://www.nature.com/articles/nrd.2022.243
[Journal of Natural Products, 2021] The Re-emergence of Natural Products for Drug Discovery in the Genomics Era | https://pubs.acs.org/doi/10.1021/acs.jnatprod.0c01303
[IQVIA, 2024] Global Oncology Trends 2024 | https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2024
[Biopharma Dive, 2024] Biopharma discovery deals surge in 2023 | https://www.biopharmadive.com/news/biopharma-discovery-deals-2023/703456/
[FDA, 2023] Oncology Center of Excellence | https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence
[Silicon Valley Bank, 2024] Healthcare Investments and Exits | https://www.svb.com/trends-insights/reports/healthcare-investments-and-exits
[BioPharma Dive] LifeMine Therapeutics raises $175M Series C | https://www.biopharmadive.com/news/lifemine-therapeutics-series-c-175m/618468/
[Crunchbase] Adapsyn Bioscience - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/adapsyn-bioscience
[Greenhouse, August 2025] Scientist I/II/Senior Scientist, Medicinal Chemistry | https://job-boards.greenhouse.io/hexagonbio/jobs/6693363003
Articles about Hexagon Bio
- Hexagon Bio Mines Fungal Genomes for a New Class of Cancer Payloads — The $185 million biotech is building a computational platform to discover novel antibody-drug conjugate components from nature's untapped chemistry.